In contrast, it exhibits prominent neoplastic overexpression in a subset of estrogen receptor-positive (ER+) primary tumors of the breast (16), going hand in hand with increased lymph node metastasis and reduced survival of patients (17–19). Here, ESR1 is linked to metastatic malignant neoplasm in the lymph nodes.